Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg  

Recombinant human HVEM/TNFRSF14 Protein, Fc Tag, 100µg

Recombinant Human HVEM /TNFRSF14 Protein, Pro37-Val202, produced in human 293 cells (HEK293), Fc Tag

Synonym
recombinant, human protein, TNFRSF14, ATAR, HVEA, HVEM, herpesvirus entry mediator

More details

HVM-H5258-100

Availability: within 7 days

360,00 €

Background
Herpesvirus entry mediator (HVEM), also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily.

HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFß (lymphotoxin a) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTßR, the receptor for lymphotoxin aß heterotrimer. The role of the HVEM LIGHT /LTß receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.[1-4]

Source
Recombinant Human HVEM /TNFRSF14 Protein, With C-Fc Tag (rhHVEM-Fc) Pro37-Val202  (Accession # NP_003811.2) was produced in human 293 cells (HEK293)

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 45.4 kDa. The protein migrates as 55-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per µg of the rhHVEM-Fc by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 µm filtered solution in 50 mM tris, 100 mM glycine, pH7.0. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Human HVEM, Fc Tag (Cat. No. HVM-H5258) ELISA bioactivity
Immobilized Human BTLA, His Tag (Cat. No. BTA-H52E0) at 5 μg/mL (100 μL/well) can bind Human HVEM, Fc Tag (Cat. No. HVM-H5258) with a linear range of 0.08-10 μg/mL (Routinely tested).
Human HVEM, Fc Tag (Cat. No. HVM-H5258) ELISA bioactivity
Immobilized Human HVEM, Fc Tag (Cat. No. HVM-H5258) at 10μg/mL (100 μL/well) can bind Biotinylated Human BTLA, Fc Tag (Cat. No. BTA-H82F8) with a linear range of 0.3-5 μg/mL (QC tested).

References

(1) Hsu, H. et al. (1997) J. Biol. Chem. 272:13471.
(2) Mauri, D.N. et al. (1998) Immunity 8:21
(3) Montgomery, R.I. et al. (1996) Cell 87:427
(4) Cheung,T.C.etal.,2005,Proc.Natl.Acad.Sci.USA102:13218-23